About the drug: The drug -- OZ439 -- tested well in Phase I clinical trials and now moves into Phase II trials.
|Jonathan Vennerstrom, Ph.D.|
Project support: Dr. Vennerstrom's research on the drug was supported by Medicines for Malaria Venture (MMV), a nonprofit organization based in Geneva, Switzerland which receives 60 percent of its funding from the Bill and Melinda Gates Foundation.
Other team members working with Dr. Vennerstrom come from Monash University in Australia and the Swiss Tropical Institute in Basel, Switzerland.
Read more: The discovery of OZ439 recently was reported in the science journal Proceedings of the National Academy of Sciences.